Compare DexCom, Inc. (DXCM) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs PubMatic Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while PubMatic Inc trades at $17.52 (market cap $804.41M). The key difference: DexCom, Inc. is far larger — about 42× PubMatic Inc's market cap. Which is the better fit depends on your goals.
| DXCM | PUBM | |
|---|---|---|
Market Cap | $33.79B | $804.41M |
Sector | Health | Technology |
52-Week High | $89.53 | $17.78 |
52-Week Low | $54.84 | $6.28 |
Enterprise Value | $33.24B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
PUBM trades at $17.18, down 3.27% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported a Q2 2026 earnings beat with 11% revenue growth, driven by mobile app and CTV segments, though it remains unprofitable with a negative net income margin. Recent news highlights strategic hires and product launches like AgenticOS to capitalize on AI in advertising.
The outlook is mixed: strong revenue growth and analyst buy ratings support upside to the $20.83 consensus target, but profitability challenges and high valuation ratios pose risks. Investors should weigh the growth potential in high-margin segments against persistent losses and competitive pressures in the ad tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
